Aaron Taylor-Johnson is a shoe-in for the next James Bond (Image: Getty) Aaron Taylor-Johnson has been dealt a huge blow as the odds of him playing the next James Bond are dwindling. It was previously reported that the star was "offered" the role of the iconic 007 spy, five years after Daniel Craig announced he was leaving the world of espionage behind him. A source close to the film previously told the press: "Bond is Aaron’s job, should he wish to accept it.
The formal offer is on the table and they are waiting to hear back. "As far as Eon is concerned, Aaron is going to sign his contract in the coming days and they can start preparing for the big announcement." function loadOvpScript(){let el=document.
createElement('script');el.setAttribute('src','https://live.primis.
tech/live/liveView.php?s=114945&playerApiId=v114945');document.getElementById('ovp-primis').
appendChild(el)}window.top.addEventListener('primisPlayerInit',e=>{try{if(e.
detail&&e.detail.playerApiId==="v114945"){if(window.
document.getElementsByClassName('jwplayer')[0]){e.detail.
float('disable')}}}catch(e){}});window.addEventListener('DOMContentLoaded',()=>{setTimeout(()=>{if(typeof flagTcfLoaded!=='undefined'&&flagTcfLoaded===!0){loadOvpScript()ExpressApp.Log('[Load] OVP flagTcfLoaded',new Date())}else{document.
addEventListener("tcfLoaded",()=>{loadOvpScript()ExpressApp.Log('[Load] OVP tcfLoaded',new Date())})}},1500)}) But the film seems to be facing more delays and there has still been no official confirmation from Bond bosses at Eon Productions. Aaron has also refused to comment on the matter.
The star told Rolling Stone earlier this year: "I can only really talk about the things I’m going to show and tell." He added: "I don’t feel like I need to have a future drawn out for me. I feel like whatever’s drawn out for me, I can f*****g do better.
" READ MORE Top 10 James Bond films ranked – Sean Connery takes three spots but not No 1 [RANKED] Daniel Craig gave up the role five years ago (Image: Getty) The Kick-Ass star attracted odds of 4/5 at bookies recently but it's now been revealed that these have drifted way out to 2/1. While this still positions him as the favourite for the part, fairbettingsites.co.
uk spokesman Andy Newton, told GB News about the shift in Taylor-Johnson's appeal. He said: "It wasn’t too long ago that Aaron Taylor-Johnson was odds-on in the ‘Next James Bond’ market - however, in recent days his price has been ‘shaken and certainly stirred’ being as big as 2/1 now. Don't miss.
.. Jeremy Clarkson's brutal one-word response as bees cause mayhem [UPDATE] EastEnders star unrecognisable 30 years after quitting soap for impressive job [INSIGHT] John Cleese brutally snubs Michael Palin as Monty Python war of words continues [LATEST] It is still unclear who will be the next 007 spy (Image: Getty) Trending SUBSCRIBE Invalid email We use your sign-up to provide content in ways you've consented to and to improve our understanding of you.
This may include adverts from us and 3rd parties based on our understanding. You can unsubscribe at any time. Read our Privacy Policy "This latest move suggests the oddsmakers are wavering on Taylor-Johnson landing the 007 role that most thought he was a shoo-in for.
"In contrast, next Bond regulars in the betting Henry Cavill, Damson Idris, Rene-Jean Page and James Norton all remain steady in the market just behind Taylor-Johnson. "(However), past fancies Tom Hiddleston and Idris Elba are no longer in the running at double-figure prices." The betting expert went on to surmise: "With this latest drift at the head of the market, I’d not be shocked to see a new betting front-runner emerge in the coming weeks as we draw closer to an announcement.
" Related articles Late Queen Elizabeth suggested playing herself in James Bond skit Andy Murray told people ‘wipe your bum’ as star bemoans breakfast arrangements Strictly's Amy Dowden says 'finally' as she confirms return to show in mere days David Attenborough gives two-word warning as BBC star asks for life advice ITV Loose Women star says NHS must offer breast cancer drug.
